NCT07211958
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07211958
Title Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation (REVEAL-ND NPM1)
Acronym REVEAL-ND NPM1
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Syndax Pharmaceuticals
Indications
Therapies
Age Groups: child | adult | senior
Covered Countries ISR

Facility Status City State Zip Country Details
Clinical Trial Site RECRUITING Batumi Adjara 6000 Georgia Details
Clinical Trial Site RECRUITING Tbilisi 0112 Georgia Details
Clinical Trial Site 1 RECRUITING Tbilisi 0159 Georgia Details
Clinical Trial Site 2 RECRUITING Tbilisi 0159 Georgia Details
Clinical Trial Site RECRUITING Tbilisi 0186 Georgia Details
Clinical Trial Site RECRUITING Jerusalem 91031 Israel Details
Clinical Trial Site RECRUITING Goyang-si 10408 South Korea Details
Clinical Trial Site RECRUITING Seoul 03080 South Korea Details
Clinical Trial Site RECRUITING Seoul 06591 South Korea Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field